Various pathways lead to the resistance to IGF1R-targeted therapy, such as compensatory RTKs activation and alternative integrin signaling [39], and diverse factors dictate the susceptibility of cancer cells to IGF1R targeting, including oncogenic states and cell identities/states [40]. Here, IGF1R is linked to cancer.